Excerpt: Drug Master Files come in several types, and knowing the difference can save sourcing teams weeks of back-and-forth with suppliers. Here’s a practical breakdown for buyers.
When evaluating a new Active Pharmaceutical Ingredient (API) supplier, one of the first questions a sourcing or regulatory team asks is: “Do you have a DMF?” But not all Drug Master Files are the same, and understanding the distinctions can prevent costly delays later in the filing process.
What Is a Drug Master File?
A Drug Master File (DMF) is a submission to a regulatory authority that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of a drug product. It is not an approval in itself — rather, it allows a manufacturer to reference proprietary information without disclosing it directly to the customer.
The Main DMF Types
In the US FDA system, DMFs are generally grouped into a few categories relevant to sourcing teams:
- Type II – Drug substance, drug substance intermediate, and material used in their preparation, or drug product. This is the type most commonly referenced for APIs.
- Type III – Packaging material.
- Type IV – Excipient, colorant, flavor, essence, or material used in their preparation.
- Type V – FDA-accepted reference information.
Europe uses a parallel but distinct mechanism called the Certificate of Suitability (CEP), issued by the EDQM, which confirms that the quality of a substance is adequately controlled by the monograph of the European Pharmacopoeia.
Why This Matters for Buyers
For a sourcing team, the practical implications are significant. A supplier holding a Type II DMF can often support multiple customer filings simultaneously, since the FDA cross-references the DMF number rather than requiring the full technical package in every submission. This can meaningfully shorten timelines for customers filing an ANDA or NDA.
However, having “a DMF” is not sufficient on its own — buyers should confirm the DMF status (active, inactive, or under review), request a Letter of Access, and verify that the DMF content aligns with the Common Technical Document (CTD) format expected by the target market’s health authority.
A Quick Checklist for Sourcing Teams
Before finalizing a supplier based on DMF claims, it’s worth confirming:
- DMF number and current status with the relevant authority
- Whether a Letter of Access has been issued to your organization
- Alignment between the DMF and the CTD module structure you need
- Any recent amendments or annual reports filed against the DMF
Getting these details right early avoids surprises during a regulatory review cycle, and it’s one of the first things our regulatory affairs team checks when qualifying a new API partner.
Regulatory Affairs Desk
The Regulatory Affairs Desk publishes updates and guidance on global filing requirements, compliance standards, and documentation practices for pharmaceutical sourcing.
